Peptron Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
627
5,159
14,320
48,298
20,576
Total Accounts Receivable
127
116
371
455
1,013
Inventories
30
146
37
237
486
Other Current Assets
32
98
115
117
1,014
Total Current Assets
816
5,520
14,843
49,107
23,089
Net Property, Plant & Equipment
4,410
4,683
4,696
7,089
28,534
Total Investments and Advances
46
70
905
90
-
Intangible Assets
1,409
1,302
1,212
1,241
1,059
Other Assets
-
-
-
375
366
Total Assets
6,680
11,576
21,656
57,902
53,049
ST Debt & Current Portion LT Debt
5,232
67
2,200
-
-
Accounts Payable
94
182
55
102
145
Other Current Liabilities
1,239
572
656
822
589
Total Current Liabilities
6,565
821
2,912
924
733
Long-Term Debt
2,778
2,200
-
2,000
2,000
Provision for Risks & Charges
1,284
1,127
1,240
1,540
1,199
Deferred Taxes
93
93
93
93
93
Other Liabilities
292
154
185
136
79
Total Liabilities
11,011
4,395
4,429
4,693
4,104
Common Equity (Total)
4,331
7,181
17,228
53,209
48,945
Total Shareholders' Equity
4,331
7,181
17,228
53,209
48,945
Total Equity
4,331
7,181
17,228
53,209
48,945
Liabilities & Shareholders' Equity
6,680
11,576
21,656
57,902
53,049

About Peptron

View Profile
Address
37-24 Yuseong-daero 1628beon-gil
Daejeon DE 34054
Korea, Republic Of
Employees -
Website http://www.peptron.co.kr
Updated 09/14/2018
Peptron, Inc. engages in the development of peptide-based medicines and novel drugs. Its products include medicines for prostate cancer, hyperpituitarism, diabetes, degenerative neuronal disease, and obesity, peptide materials, and cosmetics. The company was founded on November 21, 1997 and is headquartered in Daejeon, South Korea.